Epilene

Patient Information

Epilene® in studies has shown to significantly reduce or improve symptoms related to Epileptic Seizures, Peripheral Neuropathy, Muscle Spasticity, Mild Cognitive Impairment / Alzheimers. (Individual results may vary)

Epilepsy affects approximately 65 million people worldwide. In the United States 3 million people are affected by Epilepsy, and 1 in 26 people will develop this condition at some point in their lifetime.

Prescriber Information

Epilene® is available in 3, 8 & 15mg controlled dosage oral softgels, providing oil assisted delivery for best absorption into the body.

Patient should start with 1 dose over a 3 day period, and gradually increase until desired target dose. Effects usually take within 20-45 minutes and can last up to 12+ hours.

Patients should not drive or operate machinery while on Epilene®, nor should patients take Epilene® while pregnant.

Mechanism for Action

The mechanism for action conveys the effects on the human body. The discovery of the two cannabinoid receptors CB1 and CB2 together with that of a chemical called “anandamide”. Anandamide is an endogenous ligand, which literally means that it occurs naturally within the body (endogenous) and is a binding agent or “ligand”. The full name of anandamide is arachidonoyl ethanolamide, and has its effect by inhibiting cyclic AMP (part of the cellular energy gerneration process), through G-protein coupling in target cells, which cluster in areas of the central nervous system that mediate pain, memory, and other key functions.

Preliminary tests of pharmacology and behavioral activity support the similarity of anandamide to THC. Both anandamide and THC bind weakly to the cannabinoid type one (CB1) receptors, which are found in the brain and are called partial agonists. In contrast, cannabidiol (CBD) has little activity at CB1 but greater activity at the cannabinoid type 2 receptors (CB2) that are mostly located in the periphery, in lymphoid tissues. CB1 receptor distribution and THC binding affinity at CB1 differ between humans and rodents, which underscores the importance of conducting human clinical trials. Both THC and CBD are neuroprotective antioxidants that have been shown to inhibit NMDA-mediated excitotoxicity under conditions of traumatic head injury, stroke and degenerative brain diseases.

The discovery of the endocannabinoid system has provided new insights into a neuromodulatory scheme that may provide better explanations of, and treatments for, a wide variety of previously poorly treatable, often painful disorders.

It has recently been demonstrated that CBD also stimulates vanilloid pain receptors (VR1), inhibits uptake of the anandamide, and weakly inhibits its breakdown. These new findings have important implications in elucidating the pain-relieving, anti-inflammatory, and immunodulatory effects of CBD.

The combination of THC, CBD and essential oils in cannabis-based medicinal extracts may produce a therapeutic preparation whose benefits are greater than the sum of its parts.